Tenofovir disoproxil fumarate should be avoided in patients with moderate renal impairment and in those over age 60.
The majority of patients who receive oral antiviral therapy for chronic hepatitis B virus (HBV) infection will require long-term viral suppression, since complete eradication is unlikely. Safety data on the long-term use of some of those agents are conflicting, especially around nephrotoxicity.
This retrospective study was performed between 2000 and 2016 and involved HBV-infected patients receiving either tenofovir disoproxil fumarate (TDF) or entecavir (ETV) daily. Serial laboratory testing was performed to rigorously monitor renal function and collect detailed data regarding potential risk factors. Patients were propensity-score-matched for age, sex, baseline estimated glomerular filtration rate (eGFR), follow-up duration, and presence of …
Reviewing Author
DisclosuresNothing to disclose
DisclosuresNothing to disclose